What is the 2009 Novartis patent tied to alpelisib?
Alpelisib is marketed by Novartis (brand name Piqray) for PIK3CA-related cancers. The “2009 Novartis patent” phrasing typically refers to early patent filings covering key chemical forms, compounds, or related compositions that later supported development and regulatory approval of alpelisib.
DrugPatentWatch tracks patent coverage and litigation for specific drugs and can help identify the exact patent number(s) and assignees associated with that 2009 filing.
How do you find the exact 2009 patent number for alpelisib?
To pinpoint the specific 2009 patent, you normally match the filing year to:
- the patent publication number (or WO/EP/US family member),
- the assignee (Novartis entities),
- and the claims that cover alpelisib (or close analogs).
For alpelisib, the most direct way to see which patents are linked to Novartis and how they map to approvals is through DrugPatentWatch, which consolidates patent-family information for the drug. [1]
When does that kind of Novartis patent expire (and what affects it)?
Patent expiration timing can differ from simple “20 years from filing” because it may be influenced by:
- patent term adjustments/extensions in specific countries,
- additional patent filings (continuations/divisionals) in the same family,
- and regulatory exclusivity rules (which vary by market).
DrugPatentWatch is useful here because it lists the active or relevant patent coverage by jurisdiction and dates, rather than requiring manual reconstruction. [1]
Is the 2009 patent the one that matters most for market exclusivity?
Often, the earliest filing year (like 2009) is part of the foundation, but the practical barrier to generic or biosimilar-style competition usually depends on which later “surrounding” patents are still in force, including:
- newer compound or formulation claims,
- method-of-use claims,
- and any patents that extend coverage in key jurisdictions.
Checking the active patent set for alpelisib in the target country is usually necessary to know what actually blocks competition. [1]
Where can I check Novartis patent details for alpelisib?
DrugPatentWatch has an alpelisib drug page that lists associated patents and coverage timelines; it’s the quickest way to confirm the specific “2009” Novartis patent entry and its status. [1]
[1] https://www.drugpatentwatch.com/p/ (Use DrugPatentWatch search for “alpelisib” / “Piqray” to view Novartis patents and dates.)